Endo180 at the cutting edge of bone cancer treatment and beyond by Sturge, Justin
Journal of Pathology
J Pathol 2016
Published online in Wiley Online Library
(wileyonlinelibrary.com) DOI: 10.1002/path.4673
INVITED COMMENTARY
Endo180 at the cutting edge of bone cancer treatment
and beyond#
Justin Sturge*
School of Biological, Biomedical and Environmental Sciences, University of Hull, UK
*Correspondence to: J Sturge, School of Biological, Biomedical and Environmental Sciences, University of Hull, Cottingham Road, Hull HU6 7RX,
UK. E-mail: j.sturge@hull.ac.uk
# Commentary in relation to Engelholm LH, Melander MC, Hald A, et al. Targeting a novel bone degradation pathway in primary bone
cancer by inactivation of the collagen receptor uPARAP/Endo180. J Pathol 2015, DOI: 10.1002/path.4661.
Abstract
Skeletal bone is an attractive site for secondary tumour growth and is also home to spontaneous primary cancer.
Treatment of bone metastasis is focused on limiting the vicious cycle of bone destruction with bisphosphonates or
inhibition of receptor activator of nuclear factor-𝛋B ligand (RANKL) with the fully human monoclonal antibody
denosumab. The estimated 1 million deaths/year where bone metastasis is present, and the high healthcare costs
required for its management, have ignited intensive research into the cellular and molecular pathology of osteolysis,
involving interplay between tumour cells, bone-forming osteoblasts and bone-degrading osteoclasts. Compared to
bone metastasis, knowledge about the pathology of primary bone cancers is limited. In recent work published in this
journal, Engelholm et al provide a unique insight into how this poorly understood disease manifests and destroys
bone. For the first time they have demonstrated that a mouse monoclonal antibody targeting the collagen receptor
Endo180 (CD280, MRC2 uPARAP) can prevent osteolysis and bone destruction in a syngeneic model of advanced
osteosarcoma. Their convincing findings make an important contribution towards Endo180-based therapy being
developed as an option for the treatment of bone cancer amongst other malignancies.
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Engelholm et al have taken significant steps towards
Endo180 taking its place centre stage as a bona fide
cancer target [1]. Endocytic receptor 180 was identi-
fied by Isacke et al in 1990 as an endocytic receptor
expressed by stromal cells [2]. In 2000 the full-length
human Endo180 cDNA clone was isolated [3] and the
receptor was validated to be a novel urokinase plas-
minogen activator-associated protein (hence its alter-
native name, uPARAP) [4]. The biological roles of
Endo180 include extracellular matrix (ECM) remod-
elling as a result of its interaction with collagen via
its fibronectin type II domain (FNII) [5] and its capac-
ity to promote cell-migratory signalling pathways and
invasiveness [6–9]. In osteosarcoma cells, Endo180 is
strongly localized to sites of cell–matrix contact and
plays a fundamental role in promoting their migration
via the Rho–ROCK pathway [7]. At the tissue level in
bone, Endo180 is localized to areas of active remod-
elling [10,11] and genetic silencing or mutation of Mrc2
results in some dramatic skeletal defects [11–13].
Engelholm et al’s study shines a spotlight upon
the pathology of osteosarcoma [1]. Osteosarcoma is
the most frequent primary bone cancer (incidence
0.2–3/100 000/year) that accounts for>10% of all solid
cancers in adolescents (incidence 0.8–11/100 000/year
at age 15–19). It normally arises in the metaphysis
of long extremity bones, typically in the vicinity of
the knee, and is four times more likely to affect males
as females. The primary hallmark of osteosarcoma is
the production of excessive bony osteoid matrix by
the malignant cell population. Osteosarcoma can be
osteoblastic, chondroblastic and fibroblastic in origin,
or can be a secondary complication of Paget’s disease,
or the result of radiation therapy used for a pre-existing
pathology. Localized osteosarcoma can be treated
by chemotherapy combined with function-preserving
surgery. If osteosarcoma metastasizes to other parts
of the bone, it becomes inoperable and the only ther-
apeutic option at this advanced stage of the disease
is chemotherapy. Targeted treatments that can limit
osteosarcoma progression do not exist.
In their paper, Engelholm et al explore the role of
Endo180 as a putative therapeutic target in osteosarcoma
[1]. They meticulously analysed human osteosarcoma
tissue samples by specifically focusing their attention
on the malignant cells located at the ‘cutting edge’ of
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the tumour mass where osteolytic activity helps to cre-
ate new space for growth and expansion. By zooming
into these areas, they made an intriguing observation
regarding the potential cellular mechanisms involved in
disease progression. In contrast to the high numbers
of CD68-positive osteoclasts with high tartrate-resistant
acid phosphatase (TRAP) activity seen at the cutting
edge of secondary bone lesions derived from solid
tumours, these highly specialized bone-degrading cells
could not be found. Instead the osteolytic areas of
the tumours were abundant with Endo180-positive and
MT1-MMP-positive osteosarcoma cells that formed lay-
ers in direct contact with the bone surface.
Injection of the osteosarcoma cell line (NCTC-2472)
into the femurs of mice was used to achieve high levels
of osteolytic activity. This syngeneic mouse model reca-
pitulated the observations made in human specimens,
with abundant layers of Endo180/MT1-MMP-positive
NCTC-2472 cells sitting on bone surfaces that were
virtually devoid of osteoclasts. Treatment with the
monoclonal antibody (mAb) 5f4, which recognizes
an epitope in the first three N-terminal domains of
Endo180 [cysteine-rich domain (CRD), FNII and the
first C-type lectin domain (CTLD) out of eight, CTLD1
(Figure 1)], silences Endo180 by an unknown mech-
anism [14] and blocked the uptake of fluorescently
labelled protein fragments released from bovine bone
slices by NCTC-2472 cells. The bony fragments were
traced to lysosomes, to which collagen internalized by
Endo180 is trafficked via an endocytic pathway for its
degradation. Moreover, in the syngeneic mouse model,
the Endo180-silencing mAb 5f4 protected femoral
bone against the osteolytic destruction induced by the
presence of NCTC-2472 cells. These convincing data
add significant weight to a growing body of evidence
that dysregulated Endo180-dependent mechanisms, in
tumour cells and tumour-associated stromal cells, play
central roles in bone cancer and other malignancies [15].
In accordance with the findings of Engelholm et al
[1], targeting Endo180 by genetic silencing or treat-
ment with the neutralizing mAbs A5/158 and 39.10
can block the migratory behaviour of osteosarcoma and
other invasive tumour cell types [6,7] (Figure 1). On the
flipside, epitope-specific targeting of the cell–cell adhe-
sion function of the fourth CTLD (CTLD4) in Endo180,
using the mAb 39.10 or a dominant negative CTLD4
protein construct, was found to be sufficient to induce
invasive behaviour in normal glandular epithelial cells
via disruption of the epithelial-to-mesenchymal (EMT)
suppressor complex that it forms with the extracellular
matrix metalloproteinase inducer (EMMPRIN; CD147)
[8]. Similar to the blockade of osteosarcoma progres-
sion in femoral bone by the mAb 5f4, the de novo
invasion of prostate epithelial cells induced by expo-
sure to a stiff microenvironment can be blocked by the
mAb A5/158, which recognizes an epitope in the second
CTLD (CTLD2) of Endo180 [9]. The clinical impact
that this therapeutic strategy could have is clear from the
significant survival benefit of Endo180-negative versus
Endo180-positive tumours in prostate cancer patients
[8,9]. Together with the work of Engelholm et al [1],
these findings suggest that targeting epitopes in the
N-terminus of Endo180 (CRD, FNII, CTLD1, CTLD2),
using an antibody-based therapeutic approach, should be
considered for the treatment of malignancies associated
with the promotion of mechanotransduction pathways,
including the phosphorylation of myosin light chain-2
(p-MLC2), in stiff tissues such as the ageing prostate
gland and bone (Figure 1).
The mechanism of tumour-mediated bone degrada-
tion proposed by Engelholm et al pinpoints the malig-
nant cells in the tumour mass as the major participants
in osteolysis [1]. This finding contrasts with the pathol-
ogy that underlies the establishment and progression
of bone metastasis, which involves vicious cycles of
bone destruction driven by paracrine and autocrine sig-
nals in adjacent tumour cells, osteoblasts and osteo-
clasts [16]. Tumour cells that establish niches in the
bone interact with adjacent bone-forming osteoblasts
and bone-degrading osteoclasts, disrupting normal bone
homeostasis, where levels of its formation and degra-
dation are maintained in equal balance. By using an
in vitro model to recapitulate the bone-forming side
of this complex setting, Endo180 was identified as a
modulator of mineralized type I collagen deposition in
primary human osteoblasts that is activated by the trans-
forming growth factor-β1 (TGFβ1) and TGFβ1 receptor
(TGFβ1R) signalling axis and suppressed by paracrine
signals from adjacent tumour cells [17]. Given that the
primary hallmark of human osteosarcoma is excessive
mineralized type I collagen deposition, a reduction in its
production by the targeted blockade of Endo180 func-
tion may also contribute to limiting the bony deposits
made by osteosarcoma cells and osteoblasts associated
within the tumour mass and adjacent bone stroma [17].
A clearer understanding of how the Endo180 pathway
regulates osteoid deposition in primary and secondary
bone cancer will require its in-depth evaluation as an
anti-osteogenic target in models that recapitulate their
dominant osteosclerotic nature.
Osteolysis mediated by osteoclasts requires the for-
mation of sealing zones on the bone surface and the
localized release of cathepsin K, which is the only
enzyme capable of degrading the mineralized type
I collagen matrix of bone. In support of the model
proposed by Engelholm et al, cathepsin K expression
has been demonstrated in osteoblasts and tumour cells
associated with osteosarcoma, giant cell tumour of
bone and prostate cancer [18]. From a pathological per-
spective, it will be interesting to explore how Endo180
cooperates with cathepsin K in the contexts of primary
and secondary bone cancers; however, it would be
unlikely that a combined therapeutic approach incor-
porating cathepsin K inhibitors would be considered,
given their withdrawal from further clinical evaluation
due to their severe side-effects [16]. A better therapeu-
tic option would be neo-adjuvant therapy combining
an Endo180-targeted antibody and bisphosphonates.
Interestingly, bisphosphonates significantly decrease
Endo180 levels in the serum of patients with advanced
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Figure 1. Antibody targeting of Endo180/uPARAP in cancer. The Endo180 ectodomain is composed of cysteine-rich (CR) and fibronectin type
II (FNII) domains followed by eight C-type lectin domains (CTLD1-8) [3]. The FNII domain binds to collagen [5], CTLD2 binds to glycosylated
collagen [9] and CTLD4 binds to glycosylated CD147 [8]. Endo180 is internalized from the plasma membrane via clathrin-dependent
endocytosis [2,3]. Endosomal Endo180 is responsible for: (a) spatiotemporal activation of contractile signals via the phosphorylation of
myosin light chain-2 (p-MLC2) [7], which drives cell migration and invasion; (b) signalling via the small RhoGTPases Cdc42, Rac1 and
RhoA [6] and chemotaxis towards gradients of urokinase plasminogen activator (uPA) [6] or collagen fragments [20]; and (c) trafficking of
internalized collagen to lysosomes for degradation during osteolysis [1]. The effects of monoclonal antibody (mAb) blockade of Endo180
are shown, including: (a) 5 F4 mAb, which binds to an epitope in the first three domains of the receptor (CR, FNII, CTLD1) and silences
Endo180 via an unknown mechanism [14]; (b) A5/158 mAb, which binds to an epitope in CTLD2 [6] and decreases phosphorylated myosin
light chain (p-MLC2) [7,9]; and (c) 39.10 mAb, which binds to an epitope in CTLD4 and disrupts its binding to CD147 [8]. 5f4 mAb has been
shown to block osteolysis induced by osteosarcoma cells [1]; A5/158 mAb blocks chemotaxis towards uPA in adenocarcinoma cells [6] and
decreases p-MLC2 induced by a stiff microenvironment in 3D epithelial cell acini [9]; and 39.10 mAb blocks chemotaxis towards uPA in
adenocarcinoma cells [6] but induces invasive behaviour in 3D epithelial cell acini [8]. The different roles of Endo180 in osteolytic bone
metastasis that could be targeted using antibody-based therapy, depicted in the schematic, include chemotaxis of tumour cells to bone
[6,20], mesenchymal-to-amoeboid transition in tumour cell migration on bone surfaces [21] and tumour cell-associated osteolysis [1]
breast cancer and bone metastasis [19], suggesting that
they are associated with a common pathological path-
way and may provide an additive therapeutic advantage
if co-administered. As for the therapeutic response to
bisphosphonates, responses to Endo180-targeted ther-
apy could be monitored using serum levels of soluble
Endo180.
Endo180-dependent chemotaxis towards collagen
fragments or urokinase plasminogen activator (uPA) is
linked respectively to osteoblast recruitment to sites of
bone degradation under normal physiological conditions
[20] and the migratory behaviour of metastatic tumour
cells [6]. Once in contact with human bone surfaces,
tumour cells undergo a mesenchymal-to-amoeboid
transition in their mode of migration that is driven
by Endo180 [21]. The same scenario could help the
spread of osteosarcoma, other primary bone cancers
and secondary bone metastases originating from solid
tumours, whereby the excessive release of collagen
fragments and other peptides at the cutting edge of
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the tumour mass, or premetastatic niches, might act as
chemotactic signalling cues to coordinate their inva-
sive spread towards these secondary sites and their
transition to the highly invasive amoeboid (rounded)
mode of migration (Figure 1). Blocking this process
with Endo180-targeted antibodies could be another key
to preventing the homing of primary bone cancer cells,
and cells disseminating from primary tumours, towards
secondary sites in the bone.
In a snapshot, the advances that have been made since
Endo180 was first isolated 25 years ago have led us
towards the exciting findings of Engelholm et al [1]
reported in this issue. Over the next few years we will
hopefully be able to see Endo180-based therapeutics and
diagnostics translate into improved cancer treatment.
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